These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Stainthorpe A, Greenhalgh J, Bagust A, Richardson M, Boland A, Beale S, Duarte R, Kotas E, Banks L, Palmer D. Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384 [Abstract] [Full Text] [Related]
5. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Fleeman N, Bagust A, Boland A, Beale S, Richardson M, Krishan A, Stainthorpe A, Abdulla A, Kotas E, Banks L, Payne M. Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007 [Abstract] [Full Text] [Related]
6. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M, Rawdin A, Wong R. Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175 [Abstract] [Full Text] [Related]
7. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS. Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303 [Abstract] [Full Text] [Related]
9. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Tappenden P, Simpson E, Hamilton J, Pollard D, Clowes M, Kaltenthaler E, Meiklejohn D, Morley N. Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228 [Abstract] [Full Text] [Related]
10. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M, Hodgson R. Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113 [Abstract] [Full Text] [Related]
16. Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Fleeman N, Bagust A, Duarte R, Richardson M, Nevitt S, Boland A, Kotas E, McEntee J, Thorp N. Pharmacoecon Open; 2019 Sep; 3(3):293-302. PubMed ID: 30742256 [Abstract] [Full Text] [Related]
19. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Tappenden P, Carroll C, Stevens J, Simpson E, Thokala P, Wong R, Wright J, Auer R. Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793 [Abstract] [Full Text] [Related]